<DOC>
	<DOCNO>NCT01827163</DOCNO>
	<brief_summary>The purpose study study new treatment HER2-positive breast cancer .</brief_summary>
	<brief_title>Paclitaxel With Trastuzumab Lapatinib HER2-Positive Early Stage Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Patients must histologically confirm adenocarcinoma HER2/neu immunohistochemistry 3+ FISHamplified breast cancer ratio ≥ 2.0 Tumor size ≤ 3 cm nodenegative disease . Nodes single cell tumor cluster &lt; 0.2 mm H &amp; E IHC consider nodenegative . Patients micrometastasis ( nodes tumor cluster 0.02 0.2 cm ) allow . Further axillary dissection determine patient 's surgeon per standard care . Patients must ≥18 year age . Patients must ECOG performance status 0 1 . Treatment start within 90 day final surgical procedure breast cancer . Patients may bilateral synchronous breast tumor . Patients may receive hormonal therapy purpose chemoprevention must willing discontinue prior enrollment participate trial . If patient peripheral neuropathy , must ≤ grade 1 . Patients must willing discontinue sex hormonal therapy e.g. , birth control pill , ovarian hormonal replacement therapy , etc. , prior enrollment . Women childbearing potential must willing consent use effective contraception treatment reasonable period thereafter . Hematologic parameter : absolute neutrophil count ( ANC ) ≥1500/μL platelet count ≥100,000/μL . Nonhematologic parameter : total bilirubin must ≤ 1.5 X institutional upper limit normal ( ULN ) , transaminase ( SGOT SGPT ) ≤ 3.0 x ULN . Negative HCG pregnancy test premenopausal woman reproductive capacity woman less 12 month menopause . LVEF ECHO ( strain possible ) LVEF ≥ 50 % . If ECHO do , MUGA may perform . Patients must give write , informed consent indicate understanding willingness participate study . Patients stage IV breast cancer undergo chemotherapy , radiation therapy , immunotherapy , biotherapy current breast cancer . Pregnant breastfeeding patient . Patients concurrently active second malignancy , adequately treat nonmelanoma skin cancer situ cervical cancer . Patients unstable angina , congestive heart failure , history myocardial infarction within 12 month . Patients highrisk uncontrolled arrhythmia ( ventricular tachycardia , highgrade AV block , supraventricular arrhythmia adequately ratecontrolled ) . Patients exclude grade 3 QT prolongation ( Appendix F ) ( &gt; 500 m ) require drug may prolong QT . Subjects current active hepatic ( include hepatitis B C ) biliary disease ( exception patient Gilbert 's syndrome , asymptomatic gallstone ) . Patients active , unresolved infection . Patients sensitivity E. coli derive protein .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Paclitaxel</keyword>
	<keyword>Trastuzumab</keyword>
	<keyword>Lapatinib</keyword>
	<keyword>HER2</keyword>
	<keyword>13-002</keyword>
</DOC>